[Osteonecrosis of the jaw].
Copyright policy )[Osteonecrosis of the jaw].
The paper concerns osteonecrosis of the jaw (ONJ). It is a rare but serious clinical condition. It can develop in patients treated in oncologic doses with bisphosphonates but also with denosumab. In osteoporosis ONJ seems to be very rare. Definition, pathogenesis, risk factors, prevention and treatment, and the frequency of ONJ are presented.
Alendronate, Bone Density Conservation Agents, Diphosphonates, RANK Ligand, Osteonecrosis, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Risk Factors, Humans, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Denosumab, Jaw Diseases
Alendronate, Bone Density Conservation Agents, Diphosphonates, RANK Ligand, Osteonecrosis, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Risk Factors, Humans, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Denosumab, Jaw Diseases
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!